[Endoscopic hemostasis in bleeding gastroduodenal ulcer--a contribution to the cost aspect].
Endoscopic injections of fibrin glue for the treatment of gastroduodenal ulcer hemorrhage have been increasingly used instead of sclerosing agents since 1987. Sclerosants have the drawback that they themselves have tissue-destroying or rather ulcerogenic effects. A difficult form of administration and a relatively high price are set against the good biological properties of the fibrin glue. In a randomized study comparing fibrin glue with polidocanol there was a statistically significant lower rebleeding rate in the fibrin group. The data of this study were analysed with regard to economic aspects. They showed an improved cost-benefit and cost-effectiveness ratio of the fibrin glue compared with polidocanol.
Salm
R
R
Chirurgische Abteilung, Kreiskrankenhaus Donaueschingen.
Grund
K E
KE
Szucs
T D
TD
D003362:Cost-Benefit Analysis; D016145:Endoscopy, Digestive System / Q000191:economics*; D015718:Fibrin Tissue Adhesive / Q000008:administration & dosage / Q000191:economics*; D006801:Humans; D007267:Injections; D010438:Peptic Ulcer Hemorrhage / Q000191:economics / Q000628:therapy*; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000191:economics; D012008:Recurrence; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000191:economics; D015911:Sclerotherapy / Q000191:economics*; D016896:Treatment Outcome
D015718:Fibrin Tissue Adhesive; D012597:Sclerosing Solutions; D000077423:Polidocanol; D011092:Polyethylene Glycols